Islet Cell Carcinoma

A primary malignant neoplasm of the pancreatic ISLET CELLS. Usually it involves the non-INSULIN-producing cell types, the PANCREATIC ALPHA CELLS and the pancreatic delta cells (SOMATOSTATIN-SECRETING CELLS) in GLUCAGONOMA and SOMATOSTATINOMA, respectively.

Also Known As:

Networked: 143 relevant articles (5 outcomes, 16 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Carcinoid Tumor (Carcinoid)
2.	Neoplasms (Cancer)
3.	Thyroid Neoplasms (Thyroid Cancer)
4.	Neoplasm Metastasis (Metastasis)
5.	Medullary Carcinoma

Experts

1.	Yao, James C: 4 articles (06/2007 - 12/2004)
2.	Ajani, Jaffer A: 2 articles (10/2005 - 12/2004)
3.	Lesterhuis, W J: 1 article (12/2013)
4.	van Laarhoven, H W M: 1 article (12/2013)
5.	Berends, M: 1 article (12/2013)
6.	Wiktor, Anne E: 1 article (09/2009)
7.	Keefe, Jeannette G: 1 article (09/2009)
8.	Belongie, Kimberly J: 1 article (09/2009)
9.	Dewald, Gordon W: 1 article (09/2009)
10.	Knutson, Darlene L: 1 article (09/2009)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Islet Cell Carcinoma:

1.	Streptozocin (Streptozotocin)FDA Link 05/01/1980 - "Two patients with metastatic islet-cell carcinoma underwent multiple hepatic artery catheterizations for streptozotocin infusion. " 11/10/1973 - "Editorial: Streptozotocin for islet-cell carcinoma." 10/01/1969 - "Effects of streptozotocin in a patient with islet cell carcinoma." 01/01/1990 - "5 patients with islet cell carcinoma were treated by duodenopancreatectomy and Streptozotocin. " 12/01/2013 - "Streptozotocin-induced diabetic ketoacidosis in a patient with metastatic islet-cell carcinoma."
2.	Doxorubicin (Adriamycin)FDA LinkGeneric 07/01/1982 - "Phase II trial of doxorubicin therapy for advanced islet cell carcinoma." 07/01/1982 - "Twenty evaluable patients with advanced islet cell carcinoma were treated with doxorubicin at a dosage of 60 mg/m2 every 3-4 weeks. " 07/01/1982 - "Doxorubicin has definite therapeutic activity in islet cell carcinoma and is currently being evaluated in combination chemotherapy regimens." 09/15/1999 - "The authors retrospectively reviewed the records of all islet cell carcinoma patients under care at MSKCC who were treated with streptozocin plus doxorubicin since the publication of the study mentioned earlier. " 05/01/2000 - "Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma."
3.	Fluorouracil (Carac)FDA LinkGeneric 12/01/1992 - "This seemed to be related to the administration of cumulative doses of CTZ > or = 1,500 mg. These results demonstrate that the combination of 5-FU and CTZ has activity in islet cell carcinoma, but the occurrence of renal toxicity secondary to CTZ may limit the use of this agent." 08/01/1994 - "Twenty-one patients with advanced neuro-endocrine tumors (14 with carcinoid tumors, 7 with islet cell carcinomas) were treated with alpha-IFN and 5-FU in a Phase II study. " 12/01/1992 - "A phase II trial that used fluorouracil (5-FU) and chlorozotocin (CTZ) was performed in patients with metastatic islet cell carcinoma to determine the response rate and toxicity. " 12/01/1992 - "Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: a Southwest Oncology Group study." 01/01/1999 - "In patients with islet cell carcinoma, a combination of 5-fluorouracil (350 mg) and streptozotocin (1000-2000 mg) was used. "
4.	Octreotide (Sandostatin)FDA LinkGeneric 09/15/1990 - "This study therefore suggests that tumoral SS receptors may be the likely molecular basis for octreotide action and may be an important parameter for predicting the therapeutic efficacy of SS analogues in carcinoids and islet cell carcinomas." 09/15/1990 - "These data demonstrate (a) the high prevalence of SS receptors in the primary tumors of both carcinoids and islet cell carcinomas, (b) their presence in metastases as well, (c) their continuous expression even during long term octreotide therapy, (d) the possibility of measuring SS receptors in percutaneous needle liver biopsies, and (e) the evidence of their functionality. " 01/01/1991 - "Octreotide scintigraphy localizes somatostatin receptor-positive islet cell carcinomas." 01/01/1989 - "In secreting islet cell carcinoma, the long-acting somatostatin analogue, Sandostatin, reduces symptoms of endocrine secretion both by inhibiting peptide secretion and by acting on the target organs. " 08/01/1987 - "We used an octapeptide analogue of somatostatin, SMS 201-995, in dosages ranging from 150 to 450 micrograms/d administered subcutaneously in three daily doses for 1 to 16 months, to treat 22 patients with advanced malignant islet cell carcinomas. "
5.	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 06/01/2007 - "Preliminary results from phase II studies have shown promising results for VEGF and mTOR inhibitors in carcinoid and islet cell carcinoma and RET inhibitors in medullary thyroid carcinoma. "
6.	HormonesIBA 06/01/1996 - "A nonfunctioning islet cell carcinoma was resected and immunochemically stained for multiple hormones. " 10/01/1990 - "Islet cell carcinoma frequently produces more than one chemical product, although its clinical expression is usually restricted to a single hormone. " 07/01/1989 - "Multiple-hormone-producing islet cell carcinoma: report of a case." 09/01/1971 - "Further studies on streptozotocin therapy for a multiple-hormone-producing islet cell carcinoma." 07/01/1983 - "Although most pancreatic islet cell tumors are associated with clinically evident hormone hypersecretion, a small group have no obvious signs or symptoms of excess endocrine activity and are termed "nonfunctioning." The clinical course of eight patients with "nonfunctioning" islet cell carcinoma seen during an eight-year period was reviewed. "
7.	chlorozotocinIBA 01/01/1983 - "Phase II study of chlorozotocin in islet cell carcinoma. " 01/01/1983 - "Seventeen patients with islet cell carcinoma received chlorozotocin (CTZ). " 05/01/1982 - "We have conducted a broad phase II clinical trial of chlorozotocin in 74 patients including 28 with malignant melanoma, 18 with breast cancer, nine with non-Hodgkin's lymphoma, six with nonseminomatous testicular cancer, five with ovarian cancer, four with sarcoma, three with non-beta islet cell carcinoma of the pancreas, and one with anaplastic carcinoma of the thyroid. " 12/01/1992 - "A phase II trial that used fluorouracil (5-FU) and chlorozotocin (CTZ) was performed in patients with metastatic islet cell carcinoma to determine the response rate and toxicity. " 12/01/1992 - "Phase II trial of chlorozotocin and fluorouracil in islet cell carcinoma: a Southwest Oncology Group study."
8.	GastrinsIBA 12/01/1989 - "There remains a small group of patients with highly malignant, rapidly metastasizing, gastrin-secreting islet cell carcinomas for whom localization is simple but of little relevance. " 09/01/1976 - "Peptic ulceration in a dog associated with an islet cell carcinoma of the pancreas and an elevated plasma gastrin level." 11/01/1988 - "Signs and symptoms of Cushing's syndrome developed rapidly after total gastrectomy in a 37-yr-old man with a metastatic gastrin-secreting islet cell carcinoma. " 12/01/1994 - "A case of gastrin secreting islet cell carcinoma with multiple liver metastasis and repeated gastric bleeding." 02/01/1962 - "Mechanism of the gastric hypersecretion in the Zollinger-Ellison syndrome: successful extraction of gastrin-like activity from metastases and primary pancreatico-duodenal islet cell carcinoma."
9.	Insulin (Novolin)FDA Link 12/01/1971 - "A unique form of circulating insulin in human islet cell carcinoma." 11/01/1999 - "This high insulin staining incidence and intensity characterized most islet cell carcinomas as malignant insulinomas. " 01/01/1981 - "This is the first report of the association of an insulin-secreting islet cell carcinoma with subcutaneous nodular fat necrosis." 10/15/1998 - "Transgenic mice expressing the oncogene SV40 T antigen (Tag) in the insulin-producing beta cells of the pancreas develop islet cell carcinomas. " 06/09/1978 - "A patients with metastatic insulin-producing islet-cell carcinoma has been treated with Streptozotocin intravenously and studied by selective celiac angiography during treatment. "
10.	Somatostatin (Somatotropin Release-Inhibiting Factor)IBA 08/01/1999 - "[A case of duct-islet cell carcinoma of the pancreas positive for somatostatin immunostain]." 08/01/1987 - "Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995)." 11/01/1992 - "In a patient scanned in vivo for islet cell carcinoma with an 123I-labeled somatostatin analogue, bilateral renal cell carcinomas were also visualized; multiple bilateral renal cell carcinomas were identified on the 1- and 4-h images taken after injection of 123I-labeled somatostatin analogue. " 08/01/1987 - "This analogue of somatostatin may be appropriate for use as early therapy in patients who have symptoms from syndromes related to islet cell carcinomas but in whom there is no immediate threat from tumor progression." 01/01/1993 - "Somatostatin analogs are used in the control of hormonal hypersecretion and tumor growth of patients with acromegaly, islet cell carcinomas and carcinoids. "

Therapies and Procedures

1.	Drug Therapy (Chemotherapy) 07/01/2002 - "FDG-PET might have utility in monitoring islet cell carcinoma of the pancreas in evaluating metabolic changes following chemotherapy." 10/01/2000 - "[An effective case of hepatic arterial infusion chemotherapy based on biochemical modulation for hepatic recurrence of non-functioning islet cell carcinoma of the pancreas]." 01/01/1985 - "Chemotherapy of metastatic islet cell carcinoma. " 10/15/2005 - "The addition of intraarterial chemotherapy to HAE did not improve the outcome of patients with carcinoid tumors, but it seemed to benefit patients with islet cell carcinomas. " 12/01/2004 - "The role of systemic chemotherapy in the management of pancreatic endocrine carcinoma (islet cell carcinoma; PEC) is an area of considerable controversy. "
2.	Radiotherapy 07/01/1988 - "An unresectable, intraabdominal recurrence of a nonfunctioning islet cell carcinoma of the pancreas developed in a 56-year-old man 9 years after he achieved complete remission from extensive radiotherapy. " 09/15/1987 - "This experience, in addition to that from other published reports, suggests that radiotherapy is a useful mode for treating advanced islet cell carcinoma."
3.	Transplantation (Transplant Recipients) 02/01/1992 - "Hepaticopancreaticogastroduodenectomy with transplantation for metastatic islet cell carcinoma in childhood." 02/01/1992 - "Symptomatic islet cell carcinoma of the pancreas with liver metastasis, a rare tumor cured only by complete resection, was unresponsive to chemotherapy and was treated with hepaticopancreaticogastroduodenectomy en bloc resection with transplantation in an 11-year-old girl. "
4.	Pancreatectomy 01/01/1998 - "Nonfunctioning islet cell carcinoma--a twenty-one years survival case after distal pancreatectomy." 02/01/1983 - "Her original symptoms resolved after distal pancreatectomy and splenectomy for an islet cell carcinoma of the tail of the pancreas. " 01/01/1998 - "After distal pancreatectomy, histopathological study revealed her pancreatic tumor to be a nonfunctioning islet cell carcinoma. " 08/01/2003 - "Here, we present a case of umbilical metastasis from an islet cell carcinoma diagnosed by fine-needle aspiration in a young woman 2 yr after distal pancreatectomy. " 05/01/1992 - "Forty-four patients undergoing potentially curative distal pancreatectomies were identified: 26 patients for ductal adenocarcinoma, 12 patients for islet cell carcinoma, and six patients for cystadenocarcinoma. "
5.	Liver Transplantation 01/01/1992 - "Aim of the following study is to describe the results in 4 patients with metastasizing islet cell carcinomas, which were treated by multi-visceral upper abdominal exenteration and combined orthotopic liver transplantation." 04/01/2003 - "This case of a young female patient with ectopic ACTH-producing islet cell carcinoma of the pancreas was quite unique in that she survived for 5 years despite the acute onset and rapid progression of the multiple liver metastases at least in part due to the long-lasting favorable response to octreotide and living-related liver transplantation."